The established mission of the Methodology Core for the UAB Multidisciplinary Clinical Research Center (MCRC) is to develop and provide state of the art methodology and methodological education in the collaborative support of clinical and translational research in arthritis and musculoskeletal disease (MSD) at the local, regional, national, and international level. Toward this goal, the Methodology Core will continue to provide the statistical, epidemiological, outcomes research, statistical genetics, economics/cost effectiveness, and bioinformatics leadership and expertise required to develop and perform cutting-edge clinical research in arthritis and MSD as it pursues four broad goals are to: I. Support the design, data collection, management, and analytic efforts of the MCRC projects. II. Nurture original research in methodology applicable to clinical research in arthritis and MSD. III. Develop new investigators in the area of arthritis and MSD research. IV. Provide methodology seminars, workshops, and mini-courses to introduce the newest methodological approaches to the MCRC research base.
of this core is defined by the core's mission to assist in the design, data collection, analysis and general oversight of the proposed projects, to develop new research projects from within the research base, and provide educational opportinities to the members of the research base.
|Paulsen, Jesseca A; Ptacek, Travis S; Carter, Stephen J et al. (2017) Gut microbiota composition associated with alterations in cardiorespiratory fitness and psychosocial outcomes among breast cancer survivors. Support Care Cancer 25:1563-1570|
|Curtis, Jeffrey R; Chen, Lang; Greenberg, Jeffrey D et al. (2017) The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf 26:310-319|
|Curtis, Jeffrey R; Danila, Maria I; Chen, Lang et al. (2016) Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. J Psoriasis Psoriatic Arthritis 1:128-137|
|Stoll, Matthew L; Cron, Randy Q (2016) The microbiota in pediatric rheumatic disease: epiphenomenon or therapeutic target? Curr Opin Rheumatol 28:537-43|
|Yen, Po-Yin; Lara, Barbara; Lopetegui, Marcelo et al. (2016) Usability and Workflow Evaluation of ""RhEumAtic Disease activitY"" (READY). A Mobile Application for Rheumatology Patients and Providers. Appl Clin Inform 7:1007-1024|
|Xie, Fenglong; Yun, Huifeng; Bernatsky, Sasha et al. (2016) Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis Rheumatol 68:2612-2617|
|Stoll, M L; Kumar, R; Lefkowitz, E J et al. (2016) Fecal metabolomics in pediatric spondyloarthritis implicate decreased metabolic diversity and altered tryptophan metabolism as pathogenic factors. Genes Immun 17:400-405|
|Yan, Qi; Weeks, Daniel E; Tiwari, Hemant K et al. (2015) Rare-Variant Kernel Machine Test for Longitudinal Data from Population and Family Samples. Hum Hered 80:126-38|
|Curtis, J R; Yang, S; Chen, L et al. (2015) Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken) 67:1345-53|
|Liu, Nianjun (2015) QTL mapping - Current status and challenges: Comment on ""Mapping complex traits as a dynamic system"" by L. Sun and R. Wu. Phys Life Rev 13:194-5|
Showing the most recent 10 out of 23 publications